naltrexone / bupropion

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Mysimba. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mysimba.

For practical information about using Mysimba, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 21/07/2023

Authorisation details

Product details
Agency product number
Active substance
  • bupropion hydrochloride
  • naltrexone hydrochloride
International non-proprietary name (INN) or common name
  • naltrexone
  • bupropion
Therapeutic area (MeSH)
  • Obesity
  • Overweight
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Orexigen Therapeutics Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address
2nd Floor, Palmerston House
Fenian Street
Dublin 2

Product information

04/07/2023 Mysimba - EMEA/H/C/003687 - PSUSA/00010366/202209

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of

  • ≥ 30 kg/m2 (obese), or
  • ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)

Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings
1 rating
1 rating